Researchers at Massachusetts Eye and Ear developed a preclinical research proof of concept that shows mRNA-based therapies ...

The global macular degeneration treatment market is poised for significant growth, projected to expand from USD 9.1 billion ...

It is focusing on retinal diseases, with its most advanced ... to legal blindness when they reach their early forties. The gene therapy was acquired from US biotech AGTC in 2022 by Syncona ...

It is the first pivotal trial of a mutation-agnostic RP gene therapy and the only study to show a 0.3 or better LogMAR improvement in retinal degenerative disease, according to Nanoscope.

A team of UC Davis Health researchers has shown that CD34+ stem cells can be safely administered into retinitis pigmentosa ...

These preclinical findings could lead ... Single-Dose Gene Therapy Is Potentially Life-Changing for Adults With Hemophilia B Sep. 25, 2024 — Adults with hemophilia B saw their number of bleeding ...

ABI-110 has the potential to offer a durable and effective solution by addressing the root causes of wet AMD at the genetic ...

AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today ...

Dr. Carolina Gandara, Head of Retina Assay Development at Newcells Biotech, leads internal and external projects within the ...

Proliferative vitreoretinopathy (PVR) is an eye condition that leads to blindness and can currently only be addressed with ...

A preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent blindness ...

A team of UC Davis Health researchers has shown that CD34+ stem cells can be safely administered into retinitis pigmentosa ...